Management of Idiopathic Pulmonary Arterial Hypertension in a Patient in Trinidad: A Case Report

Nishtha Mohan 1, Dominic Dalip 2, 3, 4, Shiva Jaggernauth 5, 6

Abstract
Abnormal elevation in pulmonary arterial blood pressure without secondary causes is Idiopathic Pulmonary Arterial Hypertension (IPAH). It is imperative to establish this diagnosis because IPAH often progresses to right heart failure (RHF) and death without treatment. Right heart catheterization is the standard gold test for diagnosing pulmonary hypertension (PH); however, echocardiography is a susceptible sensitive test and the best non-invasive test. The overall management of IPAH involves supportive measures, conventional therapy, and, pending availability, PAH-targeted therapy. Upon review of the literature, there were no published case reports on IPAH in Trinidad and Tobago. We describe a case of IPAH presented at Apley Medical Centre Limited, Trinidad and Tobago, in the West Indies, emphasizing contemporary management, including using the Implantable Delivery Systems (IDS) for Remodulin injection.

Introduction
Idiopathic Pulmonary Arterial Hypertension (IPAH), formerly primary pulmonary hypertension, is an abnormal elevation in pulmonary arterial blood pressure without secondary causes [1, 2]. It is a rare disease that usually presents shortness of breath [3]. In most cases, IPAH often progresses to right heart failure (RHF) and death without treatment [2]. Echocardiography is the most sensitive test as well as the best non-invasive test; however, right heart cardiac catheterization is the standard gold test in pulmonary hypertension (PH) diagnosis [2, 4]. The overall management of IPAH involves general measures, conventional therapy, and, pending availability, PAH-targeted therapy. Despite a strategic outline, management should follow an individualized approach. Upon significant clinical deterioration while on background sildenafil monotherapy, our patient traveled abroad for further management due to the unavailability of parenteral prostanoids in Trinidad and Tobago. She opted for the novel Implantable Delivery System (IDS) for Remodulin Injection (treprostinil) instead of the traditional external pump. This newer therapeutic modality which eliminates many potential barriers to adherence associated with an external pump has not been well documented thus far. This highlights the need for further research regarding the IDS for Remodulin Injection and IPAH management because it is a progressive disease for which there is no cure.

Upon review of the literature, there were no published case reports on IPAH in Trinidad and Tobago. We describe a case of IPAH presented at Apley Medical Centre Limited, Trinidad and Tobago, in the West Indies, emphasizing contemporary management, including using the IDS for Remodulin Injection.

Case Presentation
A 33-year-old obese female presented to her cardiologist with dyspnea on exertion and pedal edema 12 months ago. She had no evidence of lung disease. Blood investigations revealed hyperlipidemia, high TSH (5.18 uIu/ml), upper limit HbA1c (6.2%), and high CRP (6.07 mg/L). Elevated D-dimer levels (283 ng/ml) prompted CT pulmonary angiogram (CTPA), which ruled out pulmonary thromboembolism (Figure 1). Hematology showed slight leukocytosis, erythrocytosis, and thrombocytopenia; however, further investigations excluded underlying hematological disorders. A Transthoracic Echocardiogram (TTE) was obtained and revealed an elevated systolic pulmonary artery pressure (RVSP) of 86.23 mmHg consistent with PH. Subsequent right heart catheterization (RHC) measured mean pulmonary artery pressure (mPAP) of 108 mmHg, pulmonary capillary wedge pressure (PCWP) of 12 mmHg, and pulmonary vascular resistance (PVR) of 16 Wood units, thereby confirming pulmonary arterial hypertension (PAH). She had no family history of PH, and she denied the use of appetite suppressants and amphetamines. Other TTE findings included dilated right ventricle, right and left atria, right ventricular pressure-volume overload, and moderate 

How to cite this article
Mohan N, Dalip D, Jaggernauth S (September 28, 2022) Management of Idiopathic Pulmonary Arterial Hypertension in a Patient in Trinidad: A Case Report. Cureus 14(9): e29699. DOI 10.7759/cureus.29699
pericardial effusion (3.1cm), which was also noted on CT imaging (Figure 2). Normal cardiac biomarkers and no evidence of congenital, valvular or left heart disease on TTE excluded underlying cardiac causes. Given the negative evaluation for associated conditions, she was diagnosed with IPAH, treated with furosemide (20mg po od), spironolactone (12.5mg po od), digoxin (0.125mg po od), sildenafil (12.5mg tid) and apixaban (5mg po od) and referred to a pulmonologist.

FIGURE 1: Pulmonary arterial enlargement with no evidence of central emboli
After two months, the patient reported 1 episode of vomiting, 1 tsp of blood, and menorrhagia lasting 10 days. The dosage of apixaban was reduced to 2.5mg, and she had a Mirena coil inserted, following which she reported light periods. Her symptoms worsened within the next month with increased dyspnea and pedal edema, associated with 20 lbs weight gain. She complained of anxiety and reduced sleep caused by orthopnea. Polysomnography revealed mild obstructive sleep apnea, and she was started on a CPAP machine which improved her sleep. Repeat TTE showed reduced RVSP from 86.23 to 58 mmHg.

Her condition significantly declined one month later. She was admitted after presenting to the clinic with findings suggestive of worsening RHF - progressive dyspnea, orthopnea by four pillows, reduced exercise tolerance, occasional dizziness, and increased pedal edema. After IV furosemide was administered, her symptoms improved, which lasted two weeks before recurrence. Following the high altitude simulation testing (HAST) procedure which deemed her fit for flight, she traveled to the United States for further investigations. She had an IDS for Remodulin Injection (treprostinil) inserted following the elevation of pulmonary artery pressure to 116 mmHg on a formal pulmonary angiogram. She was also diagnosed with Hashimoto’s thyroiditis by serology testing and treated with levothyroxine.

Although the patient remained limited by dyspnea on exertion (MRC score of 4), her mental status and edema were improved. Four months later, she traveled to the United States, where the IDS for Remodulin Injection was refilled, metolazone 2.5 mg weekly was added, and furosemide was switched to bumetanide 2 mg tid. On her return, she had significantly improved (MRC score of 1) with 20 lbs weight loss; however, she admitted to dizziness. Renal function tests and blood biochemistry were regularly monitored, and supplemental potassium was administered as necessary. Tables 1-5 highlights a summary of results.
| Parameters | Reference Range | Units | Initial | 9-mth | 12 mth |
|-----------|----------------|-------|---------|-------|--------|
| WBC       | 4.0 – 10.5     | K/uL  | 13.57   | 11.90 | 10.10  |
| NEU       | 2.5 – 7.5      |       | 7.76    | 7.90  | 6.80   |
| LYM       | 1.5 – 3.5      |       | 4.51    | 3.00  | 2.40   |
| MONO      | 0.2 – 0.8      |       | 0.90    | 0.80  | 0.60   |
| EOS       | 0.0 – 0.4      |       | 0.15    | 0.20  | 0.00   |
| BASO      | 0.0 – 0.2      |       | 0.24    | 0.00  | 0.00   |
| RBC       | 3.8 – 5.8      | M/uL  | 6.41    | 5.27  | 5.30   |
| HBA       | 11.5 – 16.5    | g/dl  | 14.28   | 11.90 | 11.20  |
| HCT       | 37 – 47        | %     | 47.34   | 36.10 | 35.70  |
| MCV       | 77 – 93        | fL    | 73.84   | 68.50 | 66.70  |
| MCH       | 27 – 32        | pg    | 22.27   | 22.60 | 21.00  |
| MCHC      | 32 – 36        | g/dl  | 30.16   | 33.00 | 31.40  |
| RDW       | 12.7 – 15.1    | %     | 16.92   | 18.90 | 18.40  |
| PLT       | 150 – 400      | K/uL  | 128.10  | 237.00| 202.00 |
| MPV       | 0 – 99         | fL    | 9.57    | 8.60  | 9.30   |

**TABLE 1: Complete Blood Count laboratory results**

WBC- White Blood Cells, NEU-Neutrophils, LYM- Lymphocytes, MONO- Monocytes, EOS- Eosinophils, BASO-Basophils, RBC- Red Blood Cells, HBA- Hemoglobin, HCT- Hematocrit, MCV- Mean Corpuscular Volume, MCH- Mean Corpuscular Hemoglobin, MCHC- Mean Corpuscular Hemoglobin Concentration, RDW- Red Cell Distribution Width, PLT- Platelet, MPV- Mean Platelet Volume
### 2D Transthoracic Echocardiogram (TTE) M-Mode Measurements

| Parameters | Reference Range | Units | Initial | 3-mth | 9-mth | 19-mth |
|------------|----------------|-------|---------|-------|-------|--------|
| AO         | 2.0 – 3.1 cm    | cm    | 3.50    | 3.50  | 3.10  | 2.50   |
| LA         | 2.7 – 3.8 cm    | cm    | 4.30    | 4.00  | 4.40  | 2.90   |
| RV         | 2.5 – 4.1 cm    | cm    | 4.80    | 4.30  | 4.20  | 1.50   |
| IVSD       | 0.6 – 0.9 cm    | cm    | 1.40    | 0.90  | 0.90  | 0.80   |
| LVIDD      | 3.8 – 5.2 cm    | cm    | 2.10    | 3.10  | 3.40  | 4.50   |
| PW         | 0.6 – 0.9 cm    | cm    | 1.20    | 0.90  | 0.70  | 0.50   |
| LVIDS      | 2.2 – 3.5 cm    | cm    | 1.30    | 2.40  | 1.80  | 2.80   |
| EF         | 54 – 74 %       | %     | 70.00   | 56.00 | 70.00 | 77.00  |
| RVSP       | >35 mmHg        | mmHg  | 86.23   | 65.43 | 68.15 | 26.68  |
| PAEDP      | >15 mmHg        | mmHg  | -       | 22.10 | -     | -      |

**TABLE 2: Transthoracic Echocardiogram (TTE) results**

AO-aortic annulus diameter, LA-left atrium, RV- right ventricle, IVSD-interventricular septum diameter, LVIDD-left ventricular internal dimension at end-diastole, PW- left ventricular posterior wall thickness at end-diastole, LVIDS- left ventricular internal dimension at end-systole, EF-ejection fraction, RVSP-right ventricular systolic pressure, PAEDP-Pulmonary Artery End-Diastolic Pressure
# Right Heart Catheterization

| Parameters     | Ref Range | Units | 13-mth Follow up |
|---------------|-----------|-------|------------------|
| RA            | 0 - 5     | mmHg  | 28/21/20         |
| RV            | 20/5      | mmHg  | 106/3/24         |
| PA            | 20/10/15  | mmHg  | 108/35/64        |
| PCWP          | 7 - 12    | mmHg  | 12/10/7          |
| SVC O2sat     | 60 - 80   | %     | 46.00            |
| RA O2sat      | 75        | %     | 36.00            |
| PA O2sat      | 75        | %     | 36.00            |
| AO O2sat      | 95 - 100  | %     | 90.00            |
| Fick (CO)     | 4 - 8     | L/min | 3.50             |
| Thermo – dilution (CO) | 4 - 8 | L/min | 3.60 |
| Fick (CI)     | 2.8 – 4.2 | L/min /m2 | 1.50 |
| Thermo – dilution (CI) | 2.8 – 4.2 | L/min /m2 | 1.60 |
| PVR           | <3.125    | WU    | 160              |
| RVSWI         | 8 - 12    | g/ m/beat /m2 | 8.90 |
| PAPi          | = 0.9     |       | 3.65             |
| mRAP/ PCWP    | = 0.9     |       | 2.80             |
| TPG           | = 12      |       | 57.00            |
| DPG           | <7        |       | 28.00            |

### TABLE 3: Right Heart Catheterization results

RA - right atrium pressure, PA - pulmonary artery, PCWP - pulmonary capillary wedge pressure, SVC O2 sat - mixed venous oxygen saturation, RA O2 sat - right atrium oxygen saturation, PA O2 sat - pulmonary artery oxygen saturation, AO O2 sat - aorta oxygen saturation, Fick (CO) - Fick's cardiac output, Thermo-dilution (CO) - thermo-dilution cardiac output, Fick (CI) - Fick's cardiac index, Thermo-dilution (CI) - Thermo-dilution cardiac index, PVR - pulmonary vascular resistance, RVSWI - right ventricular stroke work index, PAPi - pulmonary artery pulsatility index, TPG - transpulmonary gradient, DPG - diastolic pulmonary gradient.
| Parameters         | Reference Range | Units | Initial | 9-mth | 12 mth | 17-mth | 19-mth |
|--------------------|-----------------|-------|---------|-------|--------|--------|--------|
| Protein (Total)    | 65 – 83         | g/L   | 72.00   | 75.00 | 71.00  | 78.40  |
| ALB                | 35 – 52         | g/L   | 38.00   | 39.00 | 40.00  | 40.30  |
| Glob               | 23 – 35         | g/L   | 34.00   | 36.00 | 31.00  | 38.10  |
| A/G                | 1.1 – 2.5       |       | 1.10    | 1.00  | 1.30   | 1.00   |
| BUN                | 7.0 – 18.7      | mg/dL | 12.20   | 9.00  | 11.00  | 12.00  | 10.20  |
| Urea               | 15 – 40         | mg/dL | 26.00   | 19.00 | 23.00  | 21.00  |
| Creat              | 0.57 – 1.11     | mg/dL | 0.96    | 0.79  | 0.81   | 0.90   | 0.77   |
| Urate              | 2.6 – 6.0       | mg/dL | 10.50   | 4.90  | 6.90   | 10.40  |
| Na                 | 136 – 145       | mmo/L | 138.00  | 138.00| 140.00 | 137.00 | 136.00 |
| K                  | 3.5 – 5.1       | mmo/L | 4.10    | 4.80  | 3.60   | 3.80   | 3.62   |
| Cl                 | 98 – 107        | mmo/L | 103     | 106.00| 105.00 | 100.00 | 98.00  |
| Iron               | 50 – 170        | ug/dL | 26.00   | 34.00 | 23.00  | 29.00  |
| E GFR              |                 |       | 67.00   | 83.00 | 98.00  | 85.00  | 103.00 |

TABLE 4: Renal Function Tests results

ALB- albumin, Glob-globulin, A/G- albumin/globulin, BUN- blood urea nitrogen, Creat- creatinine, Na- sodium, K- potassium, Cl- chloride, EGFR- estimated glomerular filtration rate
### Table 5: Additional Investigations

| Parameters | Reference Range | Units | Initial | 12 mth | 13-mth | 17-mth |
|------------|-----------------|-------|---------|--------|---------|--------|
| CRP        | 0 – 5           | mg/l  | < 5.00  | 24.40  |         |        |
| HbA1c      | 4.5 – 6.3       | %     | 6.20    |         |         |        |
| D-dimer    | 0 – 198         | ng/ml | 283.00  |         |         |        |
| TSH        | 0.35 – 4.94     | uiu/ml|         | 10.96  |         |        |
| T3         | 0.58 – 1.59     | ng/ml |         | 0.43   |         |        |
| Bili (T1)  | 0.2 – 1.2       | mg/dl |         | 2.20   |         |        |
| Bili (D)   | = 0.2           | mg/dl |         | 0.90   |         |        |
| Bili (T)   | 0.2 – 1.2       | mg/dl |         | 1.30   |         |        |
| Alk Phos   | 31 – 125        | U/L   |         | 122.00 |         |        |
| AST        | 10 – 30         | U/L   |         | 19.00  |         |        |
| ALT        | 6 – 29          | U/L   |         | 13.00  |         |        |
| Digoxin    | 0.8 – 2.4       | ng/ml |         | 2.20   |         |        |
| BNP        | < 100           | pg/ml |         |        | 414     |        |

**Discussion**

IPAH, belonging to the WHO Group 1 PH, refers to pulmonary arterial hypertension (PAH) without a secondary cause. Formerly known as Primary Pulmonary Hypertension prior to the 5th World Symposium on Pulmonary Hypertension, IPAH is an uncommon, incurable disease with an incidence of 4 to 6 cases per million people worldwide. It is more common in females presenting in their forties [4,5].

According to the REVEAL study, our patient presented with year-long dyspnea on exertion, the most frequent presenting symptom of PAH, placing her into WHO-FC/NYHA functional class II (Table 6). Her physical examination revealed characteristic findings, including pedal edema and tricuspid regurgitation murmur [6,7]. Therefore, clinical suspicion of PH prompted diagnostic investigations.
| WHO Functional Class (FC) | Description |
|--------------------------|-------------|
| I                        | Patients with pulmonary hypertension without limitation of physical activity. Ordinary physical activity does not cause dyspnea or fatigue, chest pain or near syncope. |
| II                       | Patients with pulmonary hypertension with slight limitation of physical activity. |
| III                      | Patients with pulmonary hypertension with marked limitation of physical activity. |
| IV                       | Patients with pulmonary hypertension with inability to perform any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue are present at rest. |

**TABLE 6: WHO functional assessment for pulmonary hypertension (modified from New York Heart Association functional classification)**

Measurements taken by RHC, which represents the gold standard of PAH diagnosis, in the setting of consistent TTE findings, confirmed our patient’s diagnosis. Evidence of right ventricular hypertrophy on CXR and ECG may also be found in PH patients [4]. Upon detecting PH, Pulmonary Function Tests (PFT), Arterial Blood Gas (ABG), and CT studies are performed to identify the WHO Group to which the patient belongs, followed by blood tests and serology to evaluate which type [4,7,8]. In our patient, CTPA ruled out thromboembolism and reduced lung diffusion capacity for carbon monoxide (DLCO) was indicative of Group 1. Serology ruled out underlying connective tissue disease and hepatitis [4,8]. Furthermore, extensive blood investigations excluded secondary causes, categorizing our patient as IPAH.

Poor prognostic indicators include being over 50 years old, lower body mass index, functional class III or IV, DLCO less than or equivalent to 45% of predicted, and absence of PAH-targeted therapy [4,8,9]. Our patient had a pericardial effusion and evidence of RHF, which also confirms a poor prognosis [8,9].

Although PAH management is guided by an outlined strategy coupled with follow-up visits to monitor clinical response, it should be tailored to each patient’s co-morbidities, complications, and preferences [10]. While managing our patient’s IPAH, high HbA1c levels and positive anti-thyroglobulin antibodies were discovered; subsequently, metformin and levothyroxine were added to her regimen. Notably, the development of thyroid disease is common in PAH [8]. Our patient was also found to have mild obstructive sleep apnea; thus, we introduced a CPAP machine to ameliorate her orthopnea. Nocturnal hypoxia, which can both cause and exacerbate PH, has a high prevalence in PAH (70-80%); moreover, CPAP treatment can reduce PH symptoms [8,11].

The current PAH treatment algorithm is divided into three steps according to the Grade of Recommendation and Level of Evidence assigned by the European Society of Cardiology/European Respiratory Society [8]. Moreover, the overall treatment goal is to bring or keep the patient in WHO-FC II when possible [8]. The therapeutic strategy includes an initial approach consisting of general measures, conventional therapy, expert referral, acute vasoreactivity testing; calcium channel blockers (CCBs) in vasoreactive patients or PAH-targeted therapy in non-vasoreactive patients, and response to the initial treatment strategy [8,10]. In surgical management, transplantation is an option for eligible patients with severe disease refractory to maximal medical therapy. Interventional procedures, such as balloon atrial septostomy (BAS), are considered a temporizing measure for patients awaiting transplantation or without access to medical therapy [1,10,12-23]. Our patient adopted the general measures advised by her physician corroborated in the literature, which indicates avoiding strenuous physical activity [8,10]; recommends avoiding pregnancy (associated with a very high maternal mortality rate) [4,8,10]; recommends influenza and pneumococcal vaccinations (pneumonia is the cause of death in 7% of PAH cases) [8,10].

As there were no protocol-mandated PAH treatments in the past, conventional or supportive therapy such as anticoagulants, diuretics, and cardiac glycosides were prescribed as necessary, all of which were included in our patient’s treatment regimen [4,8,9,23-30]. Oxygen therapy would be added if SpO2 <90% [51]. Judicious use of diuretics is crucial to reduce volume overload without consequent hypotension (due to reduced cardiac output as the right heart is preload dependent), arrhythmias (due to hypokalemia), and metabolic alkalosis [23,25,27,29]. As such, renal function and blood biochemistry were regularly monitored when bumetanide and metolazone were added to our patient’s regimen, and she was treated with supplemental potassium as necessary. Studies have shown that acutely administered inotropic drugs, such as digoxin, have improved cardiac output in IPAH; however, its long-term effects remain unknown [25,27,30]. The role of anticoagulation in IPAH is controversial as the evidence in favor was derived from small, retrospective, and single-center studies [25,26]. Nonetheless, in light of our patient’s high BMI and sedentary lifestyle, as well as the theoretical risk for intrapulmonary thrombosis in an already compromised pulmonary vascular bed,
she was treated with apixaban. In contrast, the literature recommends warfarin [23,25-28].

During RHC, patients should undergo pulmonary vasoreactivity testing with a vasodilator to determine if they belong to the 10% of patients with IPAH who exhibit a positive acute vasoreactive response and, thus, will likely benefit from CCB monotherapy [32]. The potential danger is hemodynamic collapse, and as such, CCBs are contraindicated in patients with low cardiac output states and elevated right atrial pressure (>20 cm H2O) [12]. Non-vasoreactive patients initiate one or more of the three PAH-targeted drugs (Table 7), which have become the contemporary standard of practice [1]. A Japanese retrospective study attributed the improvement of hemodynamic parameters to using Endothelin Receptor Antagonists (ERA) and IV epoprostanoid [12]. A randomized trial showed similar results when survival in patients on IV epoprostanoid plus conventional therapy was compared with those on conventional therapy alone [13].

| Drug                                      | Mechanism of Action                                                                 | Clinical Benefit                                                                 |
|-------------------------------------------|-------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Calcium Channel Blockers (CCB)            |                                                                                     |                                                                                  |
| Nifedipine                                | Vasodilation against smooth muscle cell hypertrophy, hyperplasia and vasoconstriction seen in patients with IPAH | Improvement in functional class of I or II and hemodynamics                      |
| Diltiazem                                 |                                                                                     |                                                                                  |
| Amlodipine                                |                                                                                     |                                                                                  |
| Prostanoids/ Prostacyclin Analogues        |                                                                                     |                                                                                  |
| Epoprostenol                              |                                                                                     | Improvement in survival in IPAH [Barst] symptoms, exercise capacity and hemodynamics |
| Treprostinil                              | Promotion of direct arterial vasodilation and inhibition of platelet aggregation      | Improvement in symptoms and exercise capacity                                     |
| Iloprost                                  |                                                                                     | Improvement in symptoms, exercise capacity, PVR and clinical events              |
| Endothelin Receptor Antagonists (ERA)     |                                                                                     |                                                                                  |
| Bosentan                                  |                                                                                     | Improvement in functional class, exercise capacity, hemodynamics, echocardiographic and Doppler variables and time to clinical worsening |
| Ambrisentan                               | Blockade of endothelin-1 receptors as endothelin-1 (a potent vasoconstrictor) is overexpressed in the plasma and lung tissue in patients with IPAH | Improvement in symptoms, exercise capacity, hemodynamics and time to clinical worsening and time to clinical worsening of IPAH and PAH associated with CTD, HIV and Eisenmenger’s syndrome |
| Macitentan                                |                                                                                     | Improvement in exercise capacity and reduction in composite endpoint of death, AS, DLTx, initiation of prostanois or worsening of PAH |
| Phosphodiesterase Type-5 Inhibitors (PDE-5i) |                                                                                     |                                                                                  |
| Sildenafil                                 | Prevention of hydrolysis of cGMP which has vasoalidatory and antiproliferative effects on pulmonary vasculature | Improvement in functional class and exercise capacity and reduction of mPAP with all doses |
| Tadalafil                                 |                                                                                     | Favorable results on symptoms, exercise capacity, hemodynamics and time to clinical worsening |
| Soluble Guanylate Cyclase Stimulators (sGC) |                                                                                     |                                                                                  |
| Riociguat                                  | Dual mode of action, acting in synergy with endogenous NO and also directly stimulating sGC independent of NO availability | Favorable results on functional class, exercise capacity, hemodynamics and time to clinical worsening |

**TABLE 7:** Mechanisms of action and clinical benefit of calcium channel blockers and approved PAH-targeted drugs used in the medical management of Idiopathic Pulmonary Arterial Hypertension

IPAH, idiopathic pulmonary arterial hypertension; PVR, pulmonary vascular resistance; PAH, pulmonary arterial hypertension; CTD, connective tissue disease; HIV, human immunodeficiency virus; AS, atrial septostomy; DLTx, double lung transplantation; cGMP, cyclic guanosine monophosphate; mPAP, mean pulmonary artery pressure; NO; nitric oxide
Furthermore, PAH-targeted therapies can be administered in combination, sequential or initial, as simultaneously targeting different mechanisms involved yields more favorable outcomes than increasing the dose of a single drug [4]. Sequential combination therapy is the most widely utilized strategy, where a drug(s) is added to monotherapy in the event of inadequate clinical response or deterioration [1,8,10]. Our patient started on monotherapy with sildenafil, FDA approved for PAH treatment in 2005 [1]. While there is no evidence-based monotherapy [8], Phosphodiesterase-5 inhibitors (PDE 5i), the most widely prescribed PAH-targeted therapy, are typically the initial therapy prescribed [1]. Our patient underwent sequential combination therapy where a prostanoi was added to sildenafil after she was admitted for decompensated RHF. Although this contrasts with the most common combination therapy, ERA plus PDE-5i [1,4], the 2008 PACES randomized trial showed improved exercise capacity in patients on IV prostanoi and PDE-5i [1,14]. Notwithstanding, initial or upfront combination therapy has emerged as a widely accepted standard of care [1,10].

Treprostinil, a prostanoi, was added to the management of our patient using a fully implantable, programmable intravascular delivery system (IDS). Procurement of this drug, however, required the patient to take the necessary steps to acquire special authorization from the Government of Trinidad and Tobago. As the first IDS to be FDA approved for PAH therapy (2018), the novel IDS for Remodulin Injection (treprostinil) came as a breakthrough application mode in IPAH management [15,16]. It represents a beneficial alternative to previously used external pumps as it yields a 44-fold reduction of catheter-related severe bloodstream infections and a reduction of catheter thrombosis, occlusions, or kinks, as revealed by the DellVery study [16,17]. Moreover, patients experience a higher quality of life, such as taking showers without concern for getting the pump wet, sleeping without fear of catheter dislocation, reduced frequency of refillings, and reduced stigmatizations associated with the visibility of external pumps [16-18]. However, studies reveal local and systemic treprostinil-related reactions after refilling and cases of pump failure [1,16]. Similar to the participants of the DellVery study, our patient was satisfied with her IDS for intravenous treprostinil [18,19].

The only prostacyclin currently used with the IDS system is treprostinil due to its long-term thermal stability compared to epoprostenol, which is considered the most effective therapy as it is the only PAH-targeted therapy to have shown improved survival in a randomized controlled trial [1,4,16-19]. Notwithstanding, the result of another trial elucidates that continuous subcutaneous treprostinil, in addition to conventional therapy, is effective in IPAH patients as measured by improvements in exercise capacity, hemodynamics and symptoms when compared to those treated with conventional therapy alone [1,20]. Additionally, the 2010 TRIUMPH I trial in which 30% of participants had background sildenafil showed a favorable outcome evident by improved exercise capacity [1], which is in keeping with our patient’s results following sequential combination therapy with sildenafil and treprostinil.

Transplantation will be the final viable option if our patient’s condition deteriorates to WHO-FC III or IV symptoms, despite maximal dosage of medical therapy [1,8,10,22,23,35]. Both double lung (DLTx) and heart-lung (HLTx) transplantations have been performed for PAH, with studies showing similar outcomes after DLTx as after HLTx [22-35]. While DLTx is the preferred treatment, HLTx is usually reserved for PAH related to congenital heart disease and when there is significant, irreversible right or left heart failure [1,22,34]. Published reports have proposed that creating an intratral shunt by BAS allows for Eisenmenger physiology which increases left ventricular preload and systemic blood flow, consequently providing symptomatic and hemodynamic improvement [1,10,22,35,36].

The major limitation in our case report is limited therapeutic choices in the management of our patient due to the unavailability of parenteral prostanooids in Trinidad and Tobago, with the only option being inhaled illoprost.

Conclusions

In conclusion, we report a case of IPAH in Trinidad, West Indies, that was not previously reported in the literature. After detecting PH, extensive evaluation and detailed history-taking for associated causes should promptly ensue as IPAH is a progressive disease for which there is no cure. Management of our patient consisted of conventional therapy and sequential combination therapy of the PAH-targeted drugs, sildenafil, and treprostinil. Moreover, she opted for the new therapeutic modality, the IDS for Remodulin Injection, after which her symptoms and functional capacity significantly improved.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other
relationships or activities that could appear to have influenced the submitted work.

References

1. Mayeux JD, Pan IZ, Dechant J, et al.: Management of pulmonary arterial hypertension. Curr Cardiacovas Risk Rep. 2021, 15:2. 10.1007/s12170-020-00663-5
2. Rino JR, Loyd JE: Primary pulmonary hypertension. Lancet. 2005, 3:1533-44. 10.1016/s0140-6736(05)15167-4
3. Bhattacharjee S, Bhattacharjee S: Primary pulmonary hypertension: a case report. Jornal de Enam Medical College. 2012, 1:81-84. 10.3329/jemc.v11i2.11468
4. Fehari P, Sharma S: Idiopathic Pulmonary Artery Hypertension. StatPearls Publishing, Treasure Island (FL); 2018. https://pubmed.ncbi.nlm.nih.gov/29489262/
5. Simonneau G, Gatzoulis MA, Adatia I, et al.: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013, 62:D54-41. 10.1016/j.jacc.2013.10.029
6. Gan CT, Lankhaar JW, Westerhof N, et al.: Noninvasively assessed pulmonary artery stiffness predicts mortality in pulmonary arterial hypertension. Chest. 2007, 132:1906-12. 10.1378/chest.07-1246
7. Hussein MF: Pulmonary hypertension as a primary presentation for schistosomiasis, a case report of unusual presentation. Oman Med Case Reports. 2019, 2019:oma075. 10.1093/omcr/oma075
8. Galili N, Humbert M, Vachiery JL, et al.: 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and congenital Cardiology (AEPCC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016, 37:67-119. 10.1093/eurheartj/ehv517
9. Zeng W, Sun YJ, Gu Q, Xiong CM, Li Jj, He JG: The impact of pulmonary arterial hypertension-targeted therapy on survival in Chinese patients with idiopathic pulmonary arterial hypertension. Pulm Circ. 2012, 2:373-8. 10.4103/2045-8952.101665
10. Galili N, Corris PA, Frost A, et al.: Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2015, 62:D60-72. 10.1016/j.jacc.2015.10.031
11. Jiwaw FN, Escourrou P, Garcia G, Jais X, Humbert M, Roisman G: High occurrence of hypoxemic sleep respiratory disorders in precapillary pulmonary hypertension and mechanisms. Chest. 2013, 143:47-55. 10.1378/chest.11-5124
12. Ogawa A, Sato T, Tamura Y, Fukuda K, Matsubara H: Survival of Japanese patients with idiopathic/heritable pulmonary arterial hypertension. Am J Cardiol. 2017, 119:1479-84. 10.1016/j.amjcard.2017.01.015
13. Barst RJ, Rubin LJ, Long WA, et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996, 334:296-301. 10.1056/NEJM199602013340504
14. Simonneau G, Rubin LJ, Galili N, et al.: Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008, 21:521-30.. 10.7326/0003-4819-149-8-200810210-00004
15. Remodulin. (2021). Accessed: November 03, 2021: https://ir.unither.com/news/press-releases/press-release-details/2021/United-Therapeutics-Corporation-Reports-Third-Q-... 10.1056/NEJM199602013340504
16. Gongnberg-Maitland M, Bourge RC, Shapiro SM, et al.: Anticoagulation in pulmonary arterial hypertension: contemporary data from COMPERA registry. Pulm Circ. 2019, 2019:omz073. 10.1164/ajrccm.186.11.1196
17. Ewert R, Halank M, Bruch L, Ghofrani HA: Updated treatment algorithm of pulmonary arterial hypertension. Eur Heart J. 2016, 37:67-119. 10.1093/eurheartj/ehv517
18. Shapiro S, Bourge RC, Pozella P, Harris DF, Borg EH, Nelsen AC: Management of pulmonary arterial hypertension. J Clin Med. 2020, 10:2045894020907881. 10.1183/13993003.01889-2018
19. Bourge RC, Waxman AB, Gongnberg-Maitland M, et al.: Treprostinil administered to treat primary pulmonary hypertension using a fully implantable programmable intravascular delivery system: results of the delivery for PAH trial. Chest. 2016, 150:27-34. 10.1016/j.chest.2015.11.005
20. Simonneau G, Barst RJ, Galili N, et al.: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2012, 186:1196-8. 10.1164/ajrccm.186.11.1196
21. Gan CT, Lankhaar JW, Westerhof N, et al.: Noninvasively assessed pulmonary artery stiffness predicts mortality in pulmonary arterial hypertension. Chest. 2007, 132:1906-12. 10.1378/chest.07-1246
22. Stacey L, Talos M, Urtik M, et al.: Interventional and surgical treatments for pulmonary arterial hypertension. J Clin Med. 2021, 10:3590/jcm10153326
23. Fusco L, Balf D, Di Perno A: Therapeutic strategies in pulmonary hypertension. Fron Pharmacol. 2011, 2:21. 10.5389/fphar.2011.00027
24. López-Meseguer M, Quezada CA, Ramón MA, et al.: Correction: Lung and heart-lung transplantation in pulmonary arterial hypertension. Plas One. 2018, 13:e0192100. 10.1371/journal.pone.0192100
25. Galili N, Hooper MM, Humbert M, et al.: Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2019, 53:1810899. 10.1183/13993003.01889-2018
26. Stacey L, Talos M, Urtik M, et al.: Interventional and surgical treatments for pulmonary arterial hypertension. J Clin Med. 2021, 10:3590/jcm10153326
27. Fusco L, Balf D, Di Perno A: Therapeutic strategies in pulmonary hypertension. Fron Pharmacol. 2011, 2:21. 10.5389/fphar.2011.00027
28. López-Meseguer M, Quezada CA, Ramón MA, et al.: Correction: Lung and heart-lung transplantation in pulmonary arterial hypertension. Plas One. 2017, 12:e0187811. 10.1371/journal.pone.0187811
29. Hansen L, Burks M, Kingman M, Stewart T: Volume management in pulmonary arterial hypertension patients: an expert pulmonary hypertension clinician perspective. Pulm Ther. 2018, 4:15-27. 10.1007/s41103-018-0052-z
30. Patel R, Aronow WS, Patel L, Gandhi K, Desai H, Kaul D, Sahgal SP: Treatment of pulmonary hypertension. Med Sci Monit. 2012, 18:RA31-9. 10.12659/msm.882607
31. Hoeper MM, Benza RL, Corris P, et al.: Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur Respir J. 2019, 53: 10.1183/13993003.01906-2018
32. Simoneau G, Montani D, Celermajer DS, et al.: Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019, 53: 10.1183/13993003.01913-2018
33. Medarov BI, Judson MA: The role of calcium channel blockers for the treatment of pulmonary arterial hypertension: How much do we actually know and how could they be positioned today?. Respir Med. 2015, 109:557-64. 10.1016/j.rmed.2015.01.004
34. Le Pavec J, Hascoët S, Fadel E: Heart-lung transplantation: current indications, prognosis and specific considerations. J Thorac Dis. 2018, 10:5946-52. 10.21037/jtd.2018.09.115
35. Hill C, Maxwell B, Boulate D, et al.: Heart-lung vs. double-lung transplantation for idiopathic pulmonary arterial hypertension. Clin Transplant. 2015, 29:1067-75. 10.1111/ctr.12628
36. Kurzyna M, Dabrowski M, Bielecki D, et al.: Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. Chest. 2007, 131:977-83. 10.1378/chest.06-1227